InterOcean Capital Group LLC Sells 67 Shares of Danaher Co. (NYSE:DHR)

InterOcean Capital Group LLC decreased its stake in shares of Danaher Co. (NYSE:DHRFree Report) by 1.8% during the fourth quarter, HoldingsChannel reports. The firm owned 3,724 shares of the conglomerate’s stock after selling 67 shares during the quarter. InterOcean Capital Group LLC’s holdings in Danaher were worth $862,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Banco Santander S.A. purchased a new position in Danaher during the 3rd quarter valued at about $683,000. Cary Street Partners Investment Advisory LLC raised its holdings in Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after buying an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. raised its holdings in Danaher by 0.6% in the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after buying an additional 149 shares during the last quarter. Cercano Management LLC raised its holdings in Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after buying an additional 20,715 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after buying an additional 96,395 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR traded down $1.51 during mid-day trading on Thursday, reaching $265.68. The stock had a trading volume of 443,578 shares, compared to its average volume of 2,674,389. The firm has a market cap of $196.79 billion, a price-to-earnings ratio of 45.31, a PEG ratio of 4.08 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $268.98. The business has a fifty day moving average of $249.54 and a 200 day moving average of $238.04. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.36 earnings per share. Equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. TD Cowen lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird lifted their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. KeyCorp lifted their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Barclays lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Finally, Royal Bank of Canada lifted their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Check Out Our Latest Stock Analysis on DHR

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The disclosure for this sale can be found here. Insiders have sold a total of 172,540 shares of company stock valued at $43,523,481 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.